Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Cosmetics Office Aims To Achieve Three “A” List Priorities In 2002

This article was originally published in The Rose Sheet

Executive Summary

FDA's Office of Cosmetics & Colors will tackle three "A" list items and 10 "B" list goals in fiscal 2002 under the Center for Food Safety & Applied Nutrition's program priorities report issued Jan. 28
Advertisement

Related Content

Office Of Cosmetics & Colors 2003 Priorities Highlight Program Revitalization
Office Of Cosmetics & Colors 2003 Priorities Highlight Program Revitalization
FDA cosmetics enforcement
FDA cosmetics enforcement
CTFA Taps Former FDA Cosmetics Director Bailey For Chemistry Post
FDA Cosmetics Office Shifts Focus As Bioterrorism, BSE Take Priority
FDA Cosmetics & Colors Permanent Director Sought But Not Imminent
"Insufficient Data" Labeling "Framework" Should Be CFSAN Priority - CTFA
AHA "Sun Alert" Labeling Recommended In CTFA Citizen Petition
AHA "Sun Alert" Labeling Recommended In CTFA Citizen Petition
Advertisement
UsernamePublicRestriction

Register

RS010002

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel